What accelerates the healing of the donor site for a split-thickness skin graft: (a) Transforming Growth Factor-β (TGF-β), (b) Recombinant Human Growth Hormone (rhGH), (c) Epidermal Growth Factor (EGF), or (d) Platelet-Derived Growth Factor (PDGF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The healing of the donor site for a split thickness skin graft is accelerated by epidermal growth factor (EGF). EGF plays a crucial role in wound healing by stimulating epithelial cell proliferation and migration, which are essential processes for re-epithelialization of the donor site. When applied topically to the donor site, EGF binds to receptors on keratinocytes and fibroblasts, activating cellular pathways that enhance cell division and movement across the wound bed. This accelerates the formation of new epithelium, reducing the time needed for complete healing. The donor site, which is essentially a partial thickness wound, particularly benefits from EGF's ability to promote rapid epithelialization from the remaining dermal appendages. While other growth factors like platelet-derived growth factor, transforming growth factor-β, and recombinant human growth hormone also contribute to wound healing in various ways, EGF has shown specific efficacy in accelerating the healing of superficial wounds such as split thickness skin graft donor sites, as supported by studies such as 1.

Some key points to consider:

  • EGF has been shown to stimulate epithelial cell proliferation and migration, which are essential for wound healing 1.
  • The application of EGF to the donor site can accelerate the formation of new epithelium, reducing the time needed for complete healing 1.
  • Other growth factors, such as platelet-derived growth factor and transforming growth factor-β, also play a role in wound healing, but EGF has shown specific efficacy in accelerating the healing of superficial wounds 1.
  • The use of EGF in wound healing is supported by several studies, including a systematic review that found EGF to be effective in promoting wound healing 1.

Overall, the evidence suggests that EGF is the most effective growth factor in accelerating the healing of split thickness skin graft donor sites, due to its ability to stimulate epithelial cell proliferation and migration, and its specific efficacy in promoting rapid epithelialization of superficial wounds.

From the Research

Acceleration of Donor Site Healing

The healing of the donor site for a split thickness skin graft can be accelerated by various factors, including:

  • Epidermal growth factor (EGF) [ 2 ], which has been shown to stimulate growth of keratinocytes in vitro and promote wound healing.
  • Recombinant human epidermal growth factor (rhEGF) [ 3 ], which has been found to promote wound healing when combined with vacuum sealing drainage.
  • Topical application of EGF [ 4 ], which has been shown to facilitate re-epithelialisation in partial thickness wounds.

Growth Factors and Wound Healing

Growth factors such as EGF play a crucial role in wound healing by:

  • Stimulating the proliferation and migration of keratinocytes [ 2 ]
  • Promoting re-epithelialisation [ 4 ]
  • Enhancing wound healing rate and histological repair effect [ 3 ]

Regrafting of Donor Site

Regrafting of the donor site with split skin graft remnants may be beneficial for patients with poor reepithelialization potential [ 5 ], but its long-term consequences and aesthetic outcomes should be carefully considered.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Regrafting of the Split-Thickness Skin Graft Donor-Site: Is It Beneficial?

Journal of burn care & research : official publication of the American Burn Association, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.